Accelerated arterial stiffening, an important complication in diabetes, increases cardiac workload eventually leading to heart failure. The arterial wall —consisting of elastin, collagen, smooth muscle, and glycosaminoglycans— may stiffen in diabetes due to 1) advanced glycation end-product (AGE)-induced collagen cross-linking, 2) calcification, or 3) changed glycosaminoglycan composition. The exact mechanical stiffening effects of these processes are unknown. Current preclinical, state-of-the-art measurement methods characterise arterial wall mechanics under static conditions. However, AGE-induced and glycosaminoglycan-associated wall stiffening may particularly affect dynamic characteristics (viscoelasticity) — especially relevant in vivo where arteries are subject to pulsatile (blood pressure) excitation.

The novel set-up for mechanical characterisation under such dynamic conditions that was previously developed still requires a matching computer modelling framework to correctly interpret the multidimensional, dynamic measurement data. DynamX aims to 1) develop this modelling framework and 2) use it to quantify the characteristics of diabetes-associated stiffening processes by studying arteries with increased calcification, collagen cross-linking, glycosaminoglycan content, and combinations thereof. The forthcoming measurement platform —already sparking interest among international collaborators— enables realistic preclinical biomechanical arterial characterisation. Its application to diabetes-associated arterial stiffening may yield breakthrough target and focus to further treatment of patients. Furthermore, its accessibility to (inter)national collaborators will be ensured by its implementation at the independent Special Skills & Advanced Phenotyping unit at the Maastricht University Biomedical Center.